Actimab-A

Candidate & Indication Development Stage
R & D Preclinical Phase 1 Phase 2 Phase 3
Actimab-A (f.d.) CD33 AML
Newly diagnosed patients
with AML over age 60
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Actimab-A (s.d.) CD33 AML Development Discontinued
R & D Phase complete
Preclinical Phase complete
Phase 1 Phase in progress
Phase 2 Phase not started
Phase 3 Phase not started

Actimab-A is currently in a Phase 2 clinical trial for newly diagnosed Acute Myeloid Leukemia (AML) patients over the age of 60. Actimab-A targets CD33, expressed on a majority of AML cells via the antibody lintuzumab and delivers powerful Actinium-225, which kills the AML cells. Actinium-225 is one of the most potent cytotoxic isotope known to man but its energy only travels four (4) cell diameters sparing many healthy cells.